Burrill & Company Hired to Advise on International Partnerships
LOS ANGELES-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
Advanced Cell Technology has made a strategic decision to seek partners for each of these programs internationally, including regions such as Europe, the Middle East and Asia, as the company recognizes that there is strong interest in the field of stem cells worldwide. ACT has asked Burrill & Company, which it hired last year to advise on a number of strategic initiatives, to renew its focus on seeking international partners. Interested parties worldwide should contact Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology at 310-481-5124.
"We recognize that there is material interest in the stem cell and regenerative medicine field globally and will seek strong partners from the worldwide medical community to pursue our programs outside of the United States and complement the work we are doing at home. We are very pleased to continue our successful relationship with Burrill & Company and utilize their extensive global network to further these discussions,” said Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
For more information, visit "www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
Andrew Hellman, 212-732-4300